Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.62 |
| ▸ | CDK7 | P50613 | 16/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 14/20 | 0.62 |
| ▸ | CCNH | P51946 | 14/20 | 0.62 |
| ▸ | CDK9 | P50750 | 9/20 | 0.62 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.62 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.62 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.62 |
| ▸ | CDK1 | P06493 | 13/20 | 0.59 |
| ▸ | CDK4 | P11802 | 12/20 | 0.59 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.59 |
| ▸ | CCND1 | P24385 | 10/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 10/20 | 0.59 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1352935 | 0.92 | CDK2 (0.59) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL1354996 | 0.91 | CDK2 (0.58) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL1355004 | 0.91 | CDK2 (0.61) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL15117963 | 0.91 | CDK2 (0.75) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL1354408 | 0.91 | CDK2 (0.64) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL1355374 | 0.91 | CDK2 (0.67) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL1352621 | 0.90 | CDK2 (0.57) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL1355369 | 0.90 | CDK2 (0.57) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL1353989 | 0.88 | CDK2 (0.64) | CDK2CDK7CCNE1CCNHCDK9 | |
| SCHEMBL1354767 | 0.87 | CDK2 (0.59) | CDK2CDK7CCNE1CCNHCDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023857-B2 | Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2015-05-05 | — | — | US | disclosed |
| EP-2391626-B1 | SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS | Univerzita Palackého v Olomouci (CZ) | 2014-10-01 | — | — | EP | disclosed |
| EP-2391626-A2 | SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS | Univerzita Palackého v Olomouci (CZ) | 2011-12-07 | — | — | EP | disclosed |
| US-20110287111-A1 | SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2011-11-24 | — | — | US | disclosed |
| WO-2010085924-A2 | SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110287111-A1 | SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS | CDK6, CCNI, CDK2 | CDK2 3/4885CDK7 9/4885CCNE1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.